Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Pediatr Int ; 66(1): e15740, 2024.
Article in English | MEDLINE | ID: mdl-38641935

ABSTRACT

BACKGROUND: The incidence of coronavirus disease 2019 (COVID-19) in children has been increasing worldwide since the onset of the pandemic. This study examined the risk factors and characteristics of COVID-19 among pediatric patients compared to other respiratory viral infections. METHODS: This was a prospective cross-sectional study. Patients aged 0-18 years presenting with respiratory symptoms from October 2020 to December 2021 were included. Demographic and clinical data were reviewed. RESULTS: In total, 738 pediatric patients were enrolled. Of these, 48.5% had COVID-19, and 41.3% were infected with another respiratory virus. The COVID-19 incidence increased from 0.5% during the original strain outbreak (October 2020 to March 2021) to 56.5% and 73.4% during the alpha (April to June 2021) and delta (July to December 2021) periods, respectively. Children aged 6-18 years, being female, obesity, exposure to household members with COVID-19, and the delta period were risk factors for COVID-19. Being aged 1-5 years, obesity, shortness of breath, productive cough, and chest pain were associated with COVID-19 pneumonia. Children aged 5-18 years, underlying neurological disease, a history of COVID-19 pneumonia, and the delta period were associated with long COVID. CONCLUSIONS: Pediatric COVID-19 patients presenting with respiratory symptoms who are obese or have been exposed to household members with COVID-19 should be tested for COVID-19. COVID-19 patients who are obese, younger than five years old, or who present with shortness of breath, productive cough, or chest pain should be evaluated for pneumonia. COVID-19 patients with a history of COVID-19 pneumonia or underlying neurological disease should receive follow-up for long COVID.


Subject(s)
COVID-19 , Humans , Child , Female , Child, Preschool , Male , COVID-19/epidemiology , Post-Acute COVID-19 Syndrome , SARS-CoV-2 , Cross-Sectional Studies , Prospective Studies , Obesity , Dyspnea , Cough/epidemiology , Cough/etiology , Chest Pain
2.
BMJ Case Rep ; 16(12)2023 Dec 30.
Article in English | MEDLINE | ID: mdl-38160035

ABSTRACT

Vertical transmission of the dengue virus is rare and infrequently reported in the literature. We report the case of a term newborn presented with high-grade fever, generalised petechial rash and hepatomegaly at the age of 5 days, with a history of dengue fever in the mother at 3 days before delivery. The diagnosis was nearly missed because the infant's dengue NS1 antigen test was initially negative and subsequently positive. After the convalescent phase, the infant developed a new-onset fever with lethargy and drowsiness. Dengue encephalitis was diagnosed with support from a positive dengue reverse-transcriptase PCR in the cerebrospinal fluid. This report has shown the importance of clinical awareness. Early recognition of congenital dengue and vigilant monitoring will contribute to appropriate early management and decrease neonatal morbidity and mortality.


Subject(s)
Dengue , Exanthema , Pregnancy Complications, Infectious , Female , Humans , Infant, Newborn , Pregnancy , Dengue/complications , Dengue/diagnosis , Exanthema/complications , Fever/complications , Infectious Disease Transmission, Vertical , Mothers , Pregnancy Complications, Infectious/diagnosis
3.
BMC Pediatr ; 21(1): 378, 2021 09 01.
Article in English | MEDLINE | ID: mdl-34470599

ABSTRACT

BACKGROUND: Many international medical organizations recommend vitamin D supplementation for infants, especially exclusively breastfed infants. In Thailand, however, data regarding the vitamin D status in Thai infants are lacking. Such data would help to support physician decisions and guide medical practice. METHODS: Full-term, exclusively breastfed infants were randomized into two groups at 2 months of age to continue exclusive breastfeeding either without vitamin D supplementation (control group, n = 44) or with vitamin D3 supplementation at 400 IU/day (intervention group, n = 43) until 6 months of age. At 6 months, the serum vitamin D (25OHD) of the infants and their mothers, serum bone marker, and infants' growth parameters were compared between the two groups. RESULTS: The infants' serum 25OHD concentration was lower in the control group than intervention group (20.57 ± 12.66 vs. 46.01 ± 16.42 ng/mL, p < 0.01). More infants had vitamin D sufficiency (25OHD of > 20 ng/mL) in the intervention group than control group (93.0% vs. 43.2%, p < 0.01). There were no significant differences in the maternal 25OHD concentrations between the control and intervention groups (25.08 ± 7.75 vs. 23.75 ± 7.64 ng/mL, p = 0.42). Serum calcium, phosphorus, intact parathyroid hormone, alkaline phosphatase, and infants' growth parameters were comparable between the two groups. After adjustment for the confounding factors, 25OHD concentration in the intervention group was 25.66 ng/mL higher than the control group (95% confidence interval, 19.07-32.25; p < 0.001). Vitamin D supplement contributed to an 88.7% decrease in the prevalence of vitamin D insufficiency/deficiency (relative risk, 0.11; 95% confidence interval, 0.04-0.35; p < 0.01). CONCLUSIONS: Most full-term, exclusively breastfed Thai infants have serum vitamin D concentration below sufficiency level at 6 months of age. However, vitamin D supplementation (400 IU/day) improves their vitamin D status and prevents vitamin D deficiency. TRIAL REGISTRATION: The study was pre-registered in the Thai Clinical Trials Registry ( TCTR20190622001 ) on 22/06/2019.


Subject(s)
Breast Feeding , Vitamin D Deficiency , Dietary Supplements , Female , Humans , Infant , Thailand , Vitamin D , Vitamin D Deficiency/drug therapy , Vitamin D Deficiency/epidemiology , Vitamin D Deficiency/prevention & control , Vitamins
4.
Medicine (Baltimore) ; 100(7): e24787, 2021 Feb 19.
Article in English | MEDLINE | ID: mdl-33607832

ABSTRACT

RATIONALE: Tuberculosis is a common cause of phlyctenular keratoconjunctivitis, especially for patients who live in a high endemic area of tuberculosis. We report a rare case of pediatric phlyctenular keratoconjunctivitis associated with primary sinonasal tuberculosis. PATIENT CONCERNS: A 7-year-old boy presented with a 5-month history of redness of the left eye accompanied by mild visual impairment. Physical examination revealed elevated pinkish-white nodules with a circumcorneal hypervascularized lesion on the left conjunctiva. DIAGNOSIS: Computed tomography revealed an enhancing soft tissue mass in the left maxillary sinus with bone destruction. Histopathology of maxillary tissue showed chronic inflammation without granuloma. Special stain, culture and polymerase chain reaction for mycobacterium were initially negative. Left maxillary sinus tuberculosis was diagnosed by positive Mycobacterium tuberculosis polymerase chain reaction from formalin-fixed paraffin-embedded maxillary tissue. INTERVENTIONS: Two month of oral isoniazid, rifampicin, pyrazinamide, and ethambutol, followed by 10 months of oral isoniazid and rifampicin without topical eye drops agent were prescribed. OUTCOMES: Two months after initiation of treatment, the phlyctenular lesion had significantly improved. A follow-up computed tomography showed a significant reduction in the size of the maxillary sinus lesion and the extent of adjacent bone destruction. LESSONS: Primary sinonasal tuberculosis is an uncommon cause of phlyctenular keratoconjunctivitis in children. When microbiological and histopathological evidences are absent, polymerase chain reaction analysis has a crucial role in the diagnosis of tuberculosis, especially in patient with uncommon presentation.


Subject(s)
Keratoconjunctivitis/etiology , Paranasal Sinus Diseases/diagnosis , Tuberculosis/diagnosis , Antibiotics, Antitubercular/therapeutic use , Child , Child, Preschool , Female , Humans , Isoniazid/therapeutic use , Male , Mycobacterium tuberculosis/isolation & purification , Orbit/diagnostic imaging , Orbit/pathology , Paranasal Sinus Diseases/complications , Paranasal Sinus Diseases/drug therapy , Rifampin/therapeutic use , Tomography, X-Ray Computed , Tuberculosis/complications , Tuberculosis/drug therapy
5.
Pediatr Infect Dis J ; 40(3): 264-268, 2021 03 01.
Article in English | MEDLINE | ID: mdl-33427799

ABSTRACT

BACKGROUND: Children and young adults undergoing hematopoietic stem cell transplantation (HSCT) typically lose their immunity to vaccine-preventable diseases, including Japanese encephalitis (JE). Revaccination against JE in this population has not been well characterized. METHODS: This prospective study evaluated the immunogenicity of inactivated Vero cell culture-derived JE vaccine in children and young adults (<25 years of age) who had completed HSCT >1 year prior. Each patient received inactivated Vero cell culture-derived JE vaccine at enrollment and 1 month after enrollment, as well as a booster dose 13 months after enrollment. Serum JE plaque reduction neutralization test and JE-specific T lymphocyte count assay were performed at baseline, 1 month after the second dose, on the day of the booster dose, and 1 month after the booster dose. RESULTS: Thirty-seven patients were enrolled. At baseline, 15 patients (40.5%) had plaque reduction neutralization titer >10, which is considered protective. Among 22 seronegative patients, 15 (68.2%) and 19 (86.4%) exhibited seroconversion after revaccination and booster dose, respectively. Median JE-specific T lymphocyte counts also increased. Twenty of 111 (18.0%) vaccination doses resulted in self-limiting side effects. CONCLUSIONS: The inactivated Vero cell culture-derived JE vaccine may be safe and effective for immunization against JE virus in children and young adults who have undergone HSCT.


Subject(s)
Antibodies, Viral/blood , Encephalitis Virus, Japanese/immunology , Hematopoietic Stem Cell Transplantation , Japanese Encephalitis Vaccines/immunology , Transplant Recipients , Adolescent , Adult , Animals , Antibodies, Neutralizing , Child , Child, Preschool , Chlorocebus aethiops , Encephalitis, Japanese/prevention & control , Female , Humans , Immunization, Secondary , Infant , Male , Prospective Studies , Vaccines, Inactivated , Vero Cells , Young Adult
6.
Pediatr Infect Dis J ; 40(1): e18-e20, 2021 01.
Article in English | MEDLINE | ID: mdl-33060515

ABSTRACT

X-linked hyper IgM (X-HIGM) syndrome is a combined immunodeficiency disease caused by mutations in the CD40LG gene, leading to a defect in immunoglobulin (Ig) class switching recombination and effector T-cell responses. X-HIGM patients usually present in early life with pyogenic bacterial and opportunistic infections. Herein, we report a previously healthy 13-year-old Thai boy who first presented with cutaneous and meningoencephalitis cryptococcosis. Whole-exome sequencing revealed that he was hemizygous for a missense c.514T>C (p.Tyr172His) in CD40LG, confirming a diagnosis of X-HIGM. This report demonstrates that X-HIGM could have an age of onset in teens and systemic cryptococcosis could be its presenting symptoms.


Subject(s)
Hyper-IgM Immunodeficiency Syndrome , Meningitis, Cryptococcal , Adolescent , CD40 Ligand/genetics , Dermatomycoses , Face/microbiology , Face/pathology , Humans , Hyper-IgM Immunodeficiency Syndrome/complications , Hyper-IgM Immunodeficiency Syndrome/diagnosis , Hyper-IgM Immunodeficiency Syndrome/genetics , Male , Mutation/genetics , Opportunistic Infections , Skin/microbiology , Skin/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...